Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrochlorothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | CA1 | P00915 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | CA9 | Q16790 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochlorothiazide SCHEMBL9349 | 1.00 | LMNA (1.00) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL156490 | 1.00 | LMNA (1.00) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27630714 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL9508286 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27674482 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL1333333 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10408471 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10778059 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27992968 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL5929409 | 0.99 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12631648-B2 | Compounds for the detection of homocysteine and its method of preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-05-19 | — | — | US | claimed |
| US-12545641-B2 | Amphoteric fluorescent substance capable of being attached to biomaterials | C-BIOMEX CO., LTD. (KR) | 2026-02-10 | — | — | US | claimed |
| US-12491158-B2 | Liposome composition and preparation method thereof | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2025-12-09 | — | — | US | claimed |
| EP-2872637-B1 | METHOD AND SYSTEM FOR PRODUCING METHANE USING HIGH GAS FEED RATES | Krajete GmbH (AT) | 2025-11-26 | — | — | EP | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| EP-4117686-B1 | LIPOSOME COMPOSITION AND PREPARATION METHOD THEREOF | UNIV CHUNG YUAN CHRISTIAN (TW) | 2024-12-04 | — | — | EP | claimed |
| EP-4105295-B1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | C BIOMEX CO LTD (KR) | 2024-07-17 | — | — | EP | claimed |
| EP-4355764-A1 | YIELD IMPROVEMENT BY GENE COMBINATIONS | BASF SE (DE) | 2024-04-24 | — | — | EP | claimed |
| US-20240011998-A1 | COMPOUNDS FOR THE DETECTION OF HOMOCYSTEINE AND ITS METHOD OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-01-11 | — | — | US | claimed |
| US-20230338922-A1 | High-Performance Metal-Organic Frameworks As Methane Sorbents And Computational Identification Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-26 | — | — | US | claimed |
| WO-2022263285-A1 | YIELD IMPROVEMENT BY GENE COMBINATIONS | BASF SE (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105295-A1 | AMPHOTERIC FLUORESCENT SUBSTANCE CAPABLE OF BEING ATTACHED TO BIOMATERIALS | C-Biomex Co., Ltd. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220296520-A1 | LIPOSOME COMPOSITION AND PREPARATION METHOD THEREOF | CHUNG YUAN CHRISTIAN UNIVERSITY (TW) | 2022-09-22 | — | — | US | claimed |
| EP-3650444-B1 | SALT AND POLYMORPH OF BENZOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2022-09-07 | — | — | EP | claimed |
| EP-3849616-B1 | DRUG DELIVERY SYTEM FOR PLATINUM-BASED DRUGS | INST NAT SANTE RECH MED (FR) | 2022-07-13 | — | — | EP | claimed |
| WO-2022129317-A1 | MODIFIED HYALURONIC ACID AS DOPANT FOR PEDOT AND/OR PPRODOT POLYMERS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-06-23 | — | — | WO | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| CN-216662664-U | Comprehensive utilization and treatment device for sodium bicarbonate desulfurization by-products and soda ash plant waste liquid | 山东海天生物化工有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-20220095612-A1 | MICRONUTRIENT COMPOSITIONS AND SYSTEMS AND METHODS OF USING SAME | NANOCHEM SOLUTIONS INC | 2022-03-31 | — | — | US | claimed |
| WO-2022049598-A1 | COMPOUNDS FOR THE DETECTION OF HOMOCYSTEINE AND ITS METHOD OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12631648-B2 | Compounds for the detection of homocysteine and its method of preparation thereof | CTH, ARGLU1, SLC7A11 | LMNA 2818/4885CA2 673/4885CA1 873/4885 |
| US-12545641-B2 | Amphoteric fluorescent substance capable of being attached to biomaterials | EPCAM, CD44, MKI67 | LMNA 2296/4885CA2 666/4885CA1 600/4885 |
| US-20240011998-A1 | COMPOUNDS FOR THE DETECTION OF HOMOCYSTEINE AND ITS METHOD OF PREPARATION THEREOF | CTH, CBS, CFB | LMNA 2151/4885CA2 1608/4885CA1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.